INSIGHTS ON CLINICAL TRIAL PARTNERING
-
Why Bioanalysis Needs To Break Free From Manual Bottlenecks
Bioanalysis remains one of the most persistent bottlenecks in drug development, with CROs displaying inefficiencies that are no longer operational nuisances but strategic liabilities.
-
Breaking Barriers: Enhancing The Bioavailability Of Orally Delivered TPDs
The large, bulky structure of TPDs limits solubility and permeability. Enabling technologies like spray drying, hot melt extrusion, and nanomilling are key to formulating these challenging molecules.
-
Finding The Solution(s) That Meet The Needs Of Patients, Sites, And Sponsors
Poor enrollment and retention often stem from patient burden and limited site access. Learn how leveraging diverse site networks and remote support can transform the clinical trial experience.
-
Early Oncology Clinical Trials: Key Considerations To Plan For Success
This presentation outlines the key success factors driving high-impact oncology drug development, with a focus on translating innovative science into clinically and commercially meaningful outcomes.
-
Start Your Journey With Block Clinical12/10/2025
Achieve unprecedented transparency with a platform designed to help you plan, manage, and analyze patient and site support costs instantly and effortlessly.
-
Reducing The Travel Burden For Patients - The Benefits Of Mobile Vision Clinics3/11/2025
Travel to trial sites can be a major hurdle for patients considering participation, but mobile vision clinics are providing a solution to improve accessibility, capacity, and patient enrollment.
-
Navigating The Unique Attributes Of Psychedelic Drug Development1/22/2024
Join our panel of experts for an in-depth review of the FDA's guidance on psychedelic drug development, exploring necessary methodological adaptations for safety, pharmacology, and efficacy.
-
Innovative Approaches In Oncology Clinical Trials2/6/2025
By embracing innovative trial models and strategic collaborations, oncology CROs play a pivotal role in bringing novel cancer therapies to market efficiently and effectively.
-
Clinical Trials In The Age Of Cost Caps4/14/2025
On February 7, 2025, the NIH introduced a pivotal policy (NOT-OD-25-068), capping indirect cost recovery at 15% for research grants.
CLINICAL TRIAL PARTNERING SOLUTIONS
-
Our proprietary GlobalReady model covers the entire drug development journey from robust EARLY PHASE clinical foundations with ClinicReady to seamless multi-regional Late phase expansion. All managed by the one award-winning CRO, saving time and costs and delivering rigorous globally accepted data.
-
Built From The Ground Up
Block Clinical understood from the beginning that intuitive technology that integrates openly with other systems and suppliers is the key to a streamlined, affordable solution.
-
Discover a debit card designed for clinical trials, providing participants with fast, reliable payments and giving sites and sponsors clear systems that help minimize burden and improve retention.
-
Streamline workflows across all types of sites, including academic medical centers and commercial sites of varying sizes, with Advarra’s complete suite of independent oversight committees.
-
Advancing a novel therapy through clinical development is complicated. Not all therapies make it to the patients that need them.